Axsome believes that its current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Options Volatility and Implied Earnings Moves Today, February 23, 2026
- AXSM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Axsome Therapeutics price target raised to $230 from $217 at Mizuho
- Axsome Therapeutics: Strengthened Sunosi Exclusivity and Robust Late‑Stage Pipeline Underpin Buy Rating
- Axsome secures long-term SUNOSI exclusivity through Alkem settlement